$7.63
+5.76% (+$0.42)Unicycive Therapeutics, Inc. is a biotechnology company, which engages in developing novel treatments for kidney diseases. The firm investigational treatment is oxylanthanum carbonate, a novel phosphate binding agent currently under review by the U.S. Food and Drug Administration (FDA) for the treatment of hyperphosphatemia in patients with chronic kidney disease who are on dialysis. Unicycive's second investigational treatment UNI-494 is intended for the treatment of conditions related to acute kidney injury. It has been granted orphan drug designation (ODD) by the FDA for the prevention of Delayed Graft Function (DGF) in kidney transplant patients and has completed a Phase 1 dose-ranging safety study in healthy volunteers. The company was founded by Shalabh Gupta on August 18, 2016 and is headquartered in Los Altos, CA.
Cambios por Período
📊 Análisis de Calidad IGNORE
Puntuación General
30/100❌ Minervini: Tendencia Alcista FAIL
4 de 5 criterios cumplidos- ✓ Precio > SMA50
- ✓ Precio > SMA200
- ✓ SMA200 alcista
- ✓ > 30% sobre mínimo 52s
- ✗ Cerca máximo 52s
❌ Livermore: Punto Pivote FAIL
2 de 3 criterios cumplidos- ✗ Cerca de nuevo máximo
- ✓ RSI fuerte (50-80)
- ✓ Momentum positivo
❌ Darvas: Patrón de Caja FAIL
1 de 4 criterios cumplidos- ✗ Volatilidad moderada
- ✗ Pico de volumen
- ✗ Haciendo nuevos máximos
- ✓ Tendencia trimestral positiva
❌ Fundamentales Fuertes FAIL
3 de 5 criterios cumplidos- ✓ Crecimiento EPS > 20%
- ✗ Crecimiento ventas > 10%
- ✗ Margen > 5%
- ✓ Crecimiento acelerado
- ✓ Historial de crecimiento
✅ Fuerza Relativa vs Mercado PASS
5 de 5 criterios cumplidos- ✓ Trimestre fuerte > 10%
- ✓ Semestre fuerte > 15%
- ✓ Mes positivo
- ✓ RSI 50-75
- ✓ Analistas favorables